Is there a role for resection of oligometastatic disease in pancreatic ductal adenocarcinoma?

Abstract

It is estimated that approximately 80%-90% of pancreatic ductal adenocarcinoma (PDAC) will present with unresectable disease with about half of patients presenting with distant metastases. The prognosis of these patients is generally poor with an average life expectancy of approximately 6 months and a median 5-year survival of 1%. The current standard of care for metastatic PDAC patients is palliative chemotherapy, as surgery in this setting does not lead to better survival. More recently, some centers have utilized very specific patient selection to perform resection of oligometastatic disease with reported improvement in survival - with many centers using response to systemic therapy as a sign of favorable biology. We performed a literature review investigating the role of surgical resection of oligometastatic disease of the lung and liver in PDAC.

Keywords

Pancreatic cancer / pancreatic ductal adenocarcinoma / liver metastasis / oligometastatic disease / M1 / surgery / metastasectomy

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020..CA Cancer J Clin2020;70:7-30

[2] Greenlee RT,Bolden S.Cancer statistics, 2000..CA Cancer J Clin2000;50:7-33

[3] Nentwich MF,Konig A,Cataldegirmen G.Surgery for advanced and metastatic pancreatic cancer--current state and trends..Anticancer Res2012;32:1999-2002

[4] Mann O,Schneider C,Izbicki JR.Surgery for advanced and metastatic pancreatic cancer--current state and perspectives..Anticancer Res2006;26:681-6

[5] Treasure T.Oligometastatic cancer: an entity, a useful concept, or a therapeutic opportunity?.J R Soc Med2012;105:242-6 PMCID:PMC3380228

[6] Damanakis AI,Waldschmidt D.Proposal for a definition of “Oligometastatic disease in pancreatic cancer”..BMC Cancer2019;19:1261 PMCID:PMC6937989

[7] Lu F,Weiss MJ.Surgery for oligometastasis of pancreatic cancer..Chin J Cancer Res2015;27:358-67 PMCID:PMC4560742

[8] Tempero MA,Al-Hawary M.Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..J Natl Compr Canc Netw2017;15:1028-61

[9] Hackert T,Hinz U.Radical surgery of oligometastatic pancreatic cancer..Eur J Surg Oncol2017;43:358-63

[10] Michalski CW,Huser N,Hartel M,Kleeff J.Resection of primary pancreatic cancer and liver metastasis: a systematic review..Dig Surg2008;25:473-80

[11] Bockhorn M,Kutup A.Crossing the Rubicon: when pancreatic resection with curative intent ends in an R2 status. Impact of “desmoplastic pseudo-pancreatitis” and anatomical site of irresectability..Ann Surg Oncol2009;16:1212-21

[12] D’Haese JG,Ilmer M.Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer..Chirurg2020;91:628-35

[13] Yamamoto S,Takeishi T.Liver transplantation in an endostage cirrhosis patient with abdominal compartment syndrome following a spontaneous rectus sheath hematoma..J Gastroenterol Hepatol2004;19:118-9

[14] Van Oudheusden TR,Dankers PY.Targeting the peritoneum with novel drug delivery systems in peritoneal carcinomatosis: a review of the literature..Anticancer Res2015;35:627-34

[15] Sugarbaker PH.Strategies to improve local control of resected pancreas adenocarcinoma..Surg Oncol2017;26:63-70

[16] Staribratova D,Uchikov A.Adenocarcinoma of the pancreas with distant meningeal metastasis..Khirurgiia (Sofiia)2009;48-51

[17] Maeno T,Ishikawa H.Patterns of pancreatic metastasis from lung cancer..Anticancer Res1998;18:2881-4

[18] Kocic M,Zegarac M.Prognostic factors and outcomes of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer - A single tertiary institution experience..J BUON2016;21:1176-83

[19] Embuscado EE,Ricci F.Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy..Cancer Biol Ther2005;4:548-54 PMCID:PMC2771924

[20] Tsurusaki M,Oda T.Assessment of Liver Metastases Using CT and MRI Scans in Patients with Pancreatic Ductal Adenocarcinoma: Effects of Observer Experience on Diagnostic Accuracy..Cancers (Basel)2020;12: PMCID:PMC7352533

[21] Danet IM,Nagase LL,Leonardou P.Liver metastases from pancreatic adenocarcinoma: MR imaging characteristics..J Magn Reson Imaging2003;18:181-8

[22] Renz BW,Roeder F,Heinemann V.Oligometastatic Disease in Pancreatic Cancer - How to Proceed?.Visc Med2017;33:36-41 PMCID:PMC5465679

[23] Tempero MA.NCCN Guidelines Updates: Pancreatic Cancer..J Natl Compr Canc Netw2019;17:603-5

[24] Hasuike Y,Yamada M.A case report-advanced pancreas cancer with liver and lung metastases well controlled over one year by combination therapy with systemic chemotherapy, radiation and hepatic arterial infusion in an outpatient setting..Gan To Kagaku Ryoho2008;35:2117-9

[25] Schullian P,Putzer D.Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection..Eur J Surg Oncol2020;S0748-7983(20)30806-4

[26] Lee SJ,Kim SY,Shin YM.Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma..Korean J Radiol2020;21:316-24 PMCID:PMC7039725

[27] Sparchez Z,Hajjar NA.Percutaneous ultrasound guided radiofrequency and microwave ablation in the treatment of hepatic metastases. A monocentric initial experience..Med Ultrason2019;21:217-24

[28] Tachezy M,Janot M.Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis..Surgery2016;160:136-44

[29] Frigerio I,Giardino A.Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?.Ann Surg Oncol2017;24:2397-403

[30] Klein F,Guckelberger O.The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma..Gastroenterol Res Pract2012;2012:939350 PMCID:PMC3508736

[31] Alghamdi AA,Alhusani AI.Survival Outcome of Pulmonary Metastasectomy Among Patients with Sarcoma and Colorectal Primary Cancers: A Single Institute Experience..Gulf J Oncolog2018;1:56-60

[32] Nanji S,Tang E.Pulmonary metastasectomy for colorectal cancer: predictors of survival in routine surgical practice..Ann Thorac Surg2018;105:1605-12

[33] Ampollini L,Goldoni M.Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival..J Thorac Dis2017;9:S1282-S90 PMCID:PMC5653500

[34] Arnaoutakis GJ,Laheru DA.Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival..J Gastrointest Surg2011;15:1611-7 PMCID:PMC3160502

[35] Klempnauer J,Piso P.Is liver resection in metastases of exocrine pancreatic carcinoma justified?.Chirurg1996;67:366-70

[36] Robinson LA,Springett G.Pulmonary metastasectomy for suspected pancreaticobiliary cancer..J Thorac Cardiovasc Surg2016;152:75-82

[37] Downs-Canner S,Boone BA.The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas..J Surg Oncol2015;112:80-5 PMCID:PMC4509861

[38] Yamashita K,Hama N,Maeda S,Takami K,Mori M.Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma..Dig Surg2015;32:464-71

[39] Wei M,Hua J,Yu X.Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1)..BMJ Open2019;9:e033452 PMCID:PMC6924808

[40] Matsuki R,Takei H.Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report..Surg Case Rep2018;4:26 PMCID:PMC5871609